AKTX - Akari Therapeutics, Plc

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 539.39M
Enterprise Value 328.96M
Trailing P/E N/A
Forward P/E 1-6.89
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)N/A
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-1.77

Trading Information

Stock Price History

Beta (3Y Monthly) 1.94
52-Week Change 3-9.00%
S&P500 52-Week Change 32.63%
52 Week High 39.2000
52 Week Low 31.5600
50-Day Moving Average 31.9033
200-Day Moving Average 32.5309

Share Statistics

Avg Vol (3 month) 31.07M
Avg Vol (10 day) 3665.8k
Shares Outstanding 520.41M
Float 8.82M
% Held by Insiders 157.08%
% Held by Institutions 15.55%
Shares Short (Aug 15, 2019) 435.51k
Short Ratio (Aug 15, 2019) 40.44
Short % of Float (Aug 15, 2019) 4N/A
Short % of Shares Outstanding (Aug 15, 2019) 40.19%
Shares Short (prior month Jul 15, 2019) 455.28k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 210/1
Last Split Date 3Sep 17, 2015

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-92.20%
Return on Equity (ttm)-379.59%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -16.4M
Net Income Avi to Common (ttm)-13.77M
Diluted EPS (ttm)-0.8740
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)2.74M
Total Cash Per Share (mrq)0.17
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.78
Book Value Per Share (mrq)-0.08

Cash Flow Statement

Operating Cash Flow (ttm)-14.44M
Levered Free Cash Flow (ttm)-11.27M